How to reconstitute Melanotan II: mixing and storage
An unapproved tanning peptide with small human trials and reports of serious harm.
Also called: Melanotan-2, MT-II, MT2, MT-2.
Melanocortin agonists · Nonselective melanocortin receptor agonist.
Comes as: Community-reported powder vials for injection, Community-reported nasal sprays.
Mixed with: Community injection reports use bacteriostatic water; no approved reconstitution instructions exist..
Common vial sizes: 10 mg. Common water amounts: 2 mL.
- A 10 mg vial plus 2 mL water is a forum example, not a licensed preparation.
- Adding bacteriostatic water does not establish powder sterility or remove endotoxin.
- Syringe units measure volume. They are not a dose unless concentration is known.
Before mixing: No validated storage specification was found for unregulated powder.
After mixing: Users report refrigeration. No validated sterile shelf life after mixing was found.
Related to Melanotan II
- Bremelanotide: An as-needed injection for low libido before menopause; nausea is common.
- Melanotan I / Afamelanotide: The molecule in an approved EPP implant; online tanning powder is a different formulation.
- Setmelanotide: A daily injection approved for specific genetic obesity and acquired hypothalamic obesity.
- Retatrutide: An experimental weekly injection with phase 3 weight-loss results.
- GHK-Cu: A copper-binding skin peptide with small topical studies and untested systemic injections.
Sources
- 503B Bulk Drug Substances List, FDA · FDA · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, US Food and Drug Administration · 2026
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA · FDA · 2026
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, FDA · FDA · 2026
- Compounding and the FDA: Questions and Answers, FDA · FDA · 2026
- Meeting of the Pharmacy Compounding Advisory Committee, FDA · 2026
- Melanotan II tanning peptide products found to be inconsistently dosed, 2026
- Scenesse, 2026
- Scenesse, INN-afamelanotide, 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, Australian Government · Australian Government · 2026
- Don’t risk using tanning products containing melanotan, 2025
- Written questions and answers - Written questions, answers and statements - UK Parliament, 2025
- Priapism (painful erections) - NHS, NHS · 2023
- Notice of Opportunity for Hearing (NOOH) Manookian, Edward 8/5/16, 2016
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.